239 related articles for article (PubMed ID: 18176963)
21. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
22. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer.
Nakata B; Nishimura S; Ishikawa T; Ohira M; Nishino H; Kawabe J; Ochi H; Hirakawa K
Int J Oncol; 2001 Jul; 19(1):53-8. PubMed ID: 11408922
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis.
Rijkers AP; Valkema R; Duivenvoorden HJ; van Eijck CH
Eur J Surg Oncol; 2014 Jul; 40(7):794-804. PubMed ID: 24755095
[TBL] [Abstract][Full Text] [Related]
24. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.
Chen J; Cheong JH; Yun MJ; Kim J; Lim JS; Hyung WJ; Noh SH
Cancer; 2005 Jun; 103(11):2383-90. PubMed ID: 15856477
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis.
Tang S; Huang G; Liu J; Liu T; Treven L; Song S; Zhang C; Pan L; Zhang T
Eur J Radiol; 2011 Apr; 78(1):142-50. PubMed ID: 19854016
[TBL] [Abstract][Full Text] [Related]
26. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
[TBL] [Abstract][Full Text] [Related]
27. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
Orsaria P; Chiaravalloti A; Caredda E; Marchese PV; Titka B; Anemona L; Portarena I; Schillaci O; Petrella G; Palombi L; Buonomo OC
Anticancer Res; 2018 Dec; 38(12):6639-6652. PubMed ID: 30504372
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET.
Higashi T; Sakahara H; Torizuka T; Nakamoto Y; Kanamori S; Hiraoka M; Imamura M; Nishimura Y; Tamaki N; Konishi J
J Nucl Med; 1999 Sep; 40(9):1424-33. PubMed ID: 10492360
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.
Hamidian Jahromi A; Sangster G; Zibari G; Martin B; Chu Q; Takalkar A; Shi R; Shokouh-Amiri H
JOP; 2013 Jul; 14(4):466-8. PubMed ID: 23846950
[TBL] [Abstract][Full Text] [Related]
31. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
[TBL] [Abstract][Full Text] [Related]
32. Accuracy of 18F-FDG PET/CT, Multidetector CT, and MR Imaging in the Diagnosis of Pancreatic Cysts: A Prospective Single-Center Study.
Kauhanen S; Rinta-Kiikka I; Kemppainen J; Grönroos J; Kajander S; Seppänen M; Alanen K; Gullichsen R; Nuutila P; Ovaska J
J Nucl Med; 2015 Aug; 56(8):1163-8. PubMed ID: 26045314
[TBL] [Abstract][Full Text] [Related]
33. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging.
Chirindel A; Alluri KC; Chaudhry MA; Wahl RL; Pawlik TM; Herman JM; Subramaniam RM
AJR Am J Roentgenol; 2015 May; 204(5):1093-9. PubMed ID: 25905947
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.
Heinrich S; Goerres GW; Schäfer M; Sagmeister M; Bauerfeind P; Pestalozzi BC; Hany TF; von Schulthess GK; Clavien PA
Ann Surg; 2005 Aug; 242(2):235-43. PubMed ID: 16041214
[TBL] [Abstract][Full Text] [Related]
37. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.
Jung W; Jang JY; Kang MJ; Chang YR; Shin YC; Chang J; Kim SW
HPB (Oxford); 2016 Jan; 18(1):57-64. PubMed ID: 26776852
[TBL] [Abstract][Full Text] [Related]
38. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy.
Capirci C; Rampin L; Erba PA; Galeotti F; Crepaldi G; Banti E; Gava M; Fanti S; Mariani G; Muzzio PC; Rubello D
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1583-93. PubMed ID: 17503039
[TBL] [Abstract][Full Text] [Related]
39. Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer.
de Jong TL; Koopman D; van der Worp CAJ; Stevens H; Vuijk FA; Vahrmeijer AL; Mieog JSD; de Groot JB; Meijssen MAC; Nieuwenhuijs VB; Lioe-Fee GO; Jager PL; Patijn GA
Surg Oncol; 2023 Apr; 47():101909. PubMed ID: 36739788
[TBL] [Abstract][Full Text] [Related]
40. Correlation between 18F-fluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer.
Ahn SJ; Park MS; Lee JD; Kang WJ
Ann Nucl Med; 2014 Jun; 28(5):430-5. PubMed ID: 24623151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
